Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26601141 | 1.00 | SMYD3 (0.37) | SMYD3ELANEPLAUF2KLKB1 | |
| SCHEMBL30670681 | 0.81 | KMT2A (0.45) | KMT2AL3MBTL1 | |
| SCHEMBL26817401 | 0.81 | KMT2A (0.45) | KMT2AL3MBTL1 | |
| SCHEMBL17500118 | 0.79 | SMYD3 (0.36) | SMYD3ACHEOPRK1 | |
| SCHEMBL17500142 | 0.79 | SMYD3 (0.36) | SMYD3ACHEMEN1KMT2AOPRK1 | |
| SCHEMBL17500115 | 0.79 | SMYD3 (0.36) | SMYD3ACHEOPRK1 | |
| SCHEMBL17500144 | 0.79 | SMYD3 (0.36) | SMYD3ACHEMEN1KMT2AOPRK1 | |
| SCHEMBL16876331 | 0.78 | KDM5A (0.38) | ELANEPLAUF2KLKB1KDM5A | |
| SCHEMBL17874277 | 0.77 | PSMB8 (0.35) | SMYD3ACHEMEN1KMT2AL3MBTL1 | |
| SCHEMBL31547073 | 0.75 | KDM5A (0.36) | ELANEPLAUF2KLKB1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| WO-2023205507-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, SHBG, NR5A1 | SMYD3 4325/4885ELANE 4274/4885PLAU 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.